Company* (Country; Symbol)

Company* (Country; Symbol)

Product

Terms/Details (Date)

Avecia Biotechnology Inc.*

Illumigen Biosciences Inc.*

Deal for the process development and manufacture of Illumigen's lead development product, IB657

The preclinical product is being developed for treating hepatitis C and other RNA viruses; terms of the deal were not disclosed (10/31)

Cangene Corp. (Canada; TSX:CNJ)

SemBioSys Genetics Inc. (Canada; TSX:SBS)

Deal under which Cangene will manufacture insulin for SemBioSys' preclinical and early clinical trials

The deal covers processing and purification of SemBioSys' plant-produced insulin; terms of the agreement were not disclosed (11/22)

Eden Biodesign* (UK)

Epistem Ltd.* (UK)

The companies entered a contract manufacturing agreement

Eden will produce potential therapeutic proteins from a range of 250 regulator genes identified by Epistem (10/23)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

TSX = Toronto Stock Exchange.